Pre-made Ofatumumab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-392

Pre-Made Ofatumumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ofatumumab,[9] sold under the brand name Arzerra among others, is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and for the treatment of multiple sclerosis. It has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis. Ofatumumab is the first marketing application for an antibody produced by Genmab, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-392-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Ofatumumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name Ofatumumab
TargetCD20
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure3giz:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2005
Year Recommended2006
CompaniesGenmab;GlaxoSmithKline;Mundipharma International;National Cancer Centre (Singapore);Novartis;Roswell Park Cancer Institute;University Health Network
Conditions ApprovedChronic lymphocytic leukaemia
Conditions ActiveB-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Multiple sclerosis;Marginal zone B-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma
Conditions DiscontinuedNeuromyelitis optica;Pemphigus vulgaris;Rheumatoid arthritis;Waldenstrom's macroglobulinaemia
Development TechMedarex HuMAb Mouse